A U.S.-China research team has developed the world's first one-step process to convert mixed plastic waste into gasoline and hydrochloric acid with up to 95-99% efficiency, all at room temperature and ambient pressure. InterestingEngineering reports: As the authors put it, "The method supports a circular economy by converting diverse plastic waste into valuable products in a single step." To carry out the conversion, the team combines plastic waste with light isoalkanes, hydrocarbon byproducts available from refinery processes. According to the paper, the process yields "gasoline range" hydrocarbons, mainly molecules with six to 12 carbons, which are the primary component of gasoline. The recovered hydrochloric acid can be safely neutralized and reused as a raw material, potentially displacing several high-temperature, energy-intensive production routes described in the paper. "We present here a strategy for upgrading discarded PVC into chlorine-free fuel range hydrocarbons and [hydrochloric acid] in a single-stage process," the researchers said. Reported conversion efficiencies underscore the potential for real-world use. At 86 degrees Fahrenheit (30 degrees Celsius), the process reached 95 percent conversion for soft PVC pipes and 99 percent for rigid PVC pipes and PVC wires. In tests that mixed PVC materials with polyolefin waste, the method achieved a 96 percent solid conversion efficiency at 80 degrees Celsius (176 degrees Fahrenheit). The team describes the approach as applicable beyond laboratory-clean samples. "The process is suitable for handling real-world mixed and contaminated PVC and polyolefin waste streams," the paper states. SCMP points to an ECNU social media post citing the study, which characterized the achievement as a first, efficiently converting difficult-to-degrade mixed plastic waste into premium petrol at ambient temperature and pressure in a single step.

Read more of this story at Slashdot.

Struggling small biotech firms are pivoting into cryptocurrencies, rebranding as "crypto treasuries" or stockpiling digital assets like Ether and Litecoin as a last-ditch effort to boost share prices amid stalled funding and weak drug pipelines. Bloomberg reports: Shares of 180 Life Sciences Corp., now doing business as ETHZilla, tripled after the Peter Thiel-backed company said it had accumulated Ether tokens worth over $350 million. Less than two weeks later, the stock's gains have been erased. In July, Sonnet BioTherapeutics Holdings soared 243% in one volatile session on plans to transform into a public crypto treasury while MEI Pharma Inc. initially doubled on plans to sell shares to fund a Litecoin treasury. Such about-faces are a tried-and-true formula for small firms when funds are low and shares are under pressure. For drugmakers it can be a sudden shift to chase after trendy new treatment targets, still other companies rebrand with buzzwords like artificial intelligence to juice returns. Now some biotech executives are using digital coins to pump new life into flagging shares. So far in 2025, at least 10 biotechs have announced a pivot into digital assets. The announcements frequently spark frenzied, but short-lived, spikes in shares. "If they're low on ideas, if they can't find relevance in drug development, they're going to try to justify their existence as management in another way," according to Mike Taylor, lead portfolio manager of the Simplify Health Care ETF. "You have a handful of companies trying to reinvent themselves into some other tangent. And, most, if not all won't work out."

Read more of this story at Slashdot.

"For a few dozen people in the world, the downside of living with a rare immune condition comes with a surprising superpower — the ability to fight off all viruses..." notes an announcement from Columbia University. "At first, the condition only seemed to increase vulnerability to some bacterial infections. But as more patients were identified, its unexpected antiviral benefits became apparent." Columbia immunologist Dusan Bogunovic discovered the individuals' antiviral powers about 15 years ago, soon after he identified the genetic mutation that causes the condition... Bogunovic, a professor of pediatric immunology at Columbia University's Vagelos College of Physicians and Surgeons, soon learned that everyone with the mutation, which causes a deficiency in an immune regulator called ISG15, has mild, but persistent systemic inflammation... "In the back of my mind, I kept thinking that if we could produce this type of light immune activation in other people, we could protect them from just about any virus," Bogunovic says. Today, Bogunovic is closing in on a therapeutic strategy that could provide that broad-spectrum protection against viruses and become an important weapon in next pandemic. In his latest study, published August 13 in Science Translational Medicine, Bogunovic and his team report that an experimental therapy they've developed temporarily gives recipients (hamsters and mice, so far) the same antiviral superpower as people with ISG15 deficiency. When administered prophylactically into the animals' lungs via a nasal drip, the therapy prevented viral replication of influenza and SARS-CoV-2 viruses and lessened disease severity. In cell culture, "we have yet to find a virus that can break through the therapy's defenses," Bogunovic says... Bogunovic's therapeutic turns on production of 10 proteins that are primarily responsible for the broad antiviral protection. The current design resembles COVID mRNA vaccines but with a twist: Ten mRNAs encoding the 10 proteins are packaged inside a lipid nanoparticle. Once the nanoparticles are absorbed by the recipient's cells, the cells generate the ten host proteins to produce the antiviral protection. "We only generate a small amount of these ten proteins, for a very short time, and that leads to much less inflammation than what we see in ISG15-deficient individuals," Bogunovic says. "But that inflammation is enough to prevent antiviral diseases...." "We believe the technology will work even if we don't know the identity of the virus," Bogunovic says. Importantly, the antiviral protection provided by the technology will not prevent people from developing their own immunological memory to the virus for longer-term protection. "Our findings reinforce the power of research driven by curiosity without preconceived notions," Bogunovic says in the announcement. "We were not looking for an antiviral when we began studying our rare patients, but the studies have inspired the potential development of a universal antiviral for everyone." More coverage from ScienceAlert.

Read more of this story at Slashdot.

Wedneday Beyond Meat "missed Wall Street estimates for second-quarter revenue," reports Reuters. "Consumers' growing concerns about processed foods are severely diminishing the appeal of Beyond Meat's product line, causing retailers and quick service restaurants to pull back sharply on orders," Rachel Wolff, analyst at Emarketer, said. Retail sales of refrigerated plant-based meat alternative products in the U.S. have fallen 17.2% so far this year, and frozen plant-based meat alternatives have fallen 8.1%, according to data from SPINS... [Beyond's] revenue for the quarter ended June 28 fell nearly 20% to $75 million, compared with analysts' average estimate of $82 million, according to data compiled by LSEG. While the company arguably invented a new market for plant-based meat substitutes, it also "owns no real intellectual property," argues The Street. "And every company in the meat and grocery business (more or less) now sells a take-off of a product that already had limited appeal..." Beyond Meat has admitted it's in trouble by hiring corporate restructuring expert John Boken from consultancy AlixPartners as interim chief transformation officer [with a focus that includes "operating expense reduction" and "broader operational efficiency"]. It has also let go of 44 employees in North America (6% of its global workforce) as it seeks to cut operating expenses amid disappointing sales... Beyond Meat also has a significant cash problem. As of June 28, 2025, Beyond Meat's cash and cash equivalents balance was $117.3 million, and total outstanding debt was $1.2 billion. The company does have time to fend off a Chapter 11 bankruptcy filing, but it also has limited, if any, prospects to meet its impending cash needs.

Read more of this story at Slashdot.

San Francisco-based startup Orchid Health "screens embryos for thousands of potential future illnesses," reports the Washington Post, calling it "the first company to say it can sequence an embryo's entire genome of 3 billion base pairs." It uses as few as five cells from an embryo to test for more than 1,200 of these uncommon single-gene-derived, or monogenic, conditions. The company also applies custom-built algorithms to produce what are known as polygenic risk scores, which are designed to measure a future child's genetic propensity for developing complex ailments later in life, such as bipolar disorder, cancer, Alzheimer's disease, obesity and schizophrenia. Orchid, [founder Noor] Siddiqui said in a tweet, is ushering in "a generation that gets to be genetically blessed and avoid disease." Right now, at $2,500 per embryo-screening on top of the average $20,000 for a single cycle of IVF, Siddiqui's social network in Silicon Valley and other tech hubs is an ideal target market... Yet several genetic scientists told The Post they doubt Orchid's core claim: that it can accurately sequence an entire human genome from just five cells collected from an early-stage embryo, enabling it to see many more single- and multiple-gene-derived disorders than other methods have. Experts have struggled to extract accurate genetic information from small embryonic samples, said Svetlana Yatsenko, a Stanford University pathology professor who specializes in clinical and research genetics. Genetic tests that use saliva or blood samples typically collect hundreds of thousands of cells. For its vastly smaller samples, Orchid uses a process called amplification, which creates copies of the DNA retrieved from the embryo. That process, Yatsenko said, can introduce major inaccuracies. "You're making many, many mistakes in the amplification," she said, rendering it problematic to declare any embryo free of a particular disease, or positive for one. "It's basically Russian roulette...." Numerous fertility doctors and scientists also told The Post they have serious reservations about screening embryos through polygenic risk scoring, the technique that allows Orchid and other companies to predict future disease by tying clusters of hundreds or even thousands of genes to disease outcomes and in some cases to other traits, such as intelligence and height. The vast majority of diseases that afflict humans are associated with many different genes rather than a single gene... And for traits such as intelligence, polygenic scoring has almost negligible predictive capacity — just a handful of IQ points... Or parents might select against an unwanted trait, such as schizophrenia, without understanding how they may be screening out desired traits associated with the same genes, such as creativity... The American College of Medical Genetics and Genomics calls the benefits of screening embryos for polygenic risks "unproven" and warns that such tests "should not be offered" by clinicians. A pioneer of polygenic risk scores, Harvard epidemiology professor Peter Kraft, has criticized Orchid, saying on X that "the science doesn't add up" and that "waving a magic wand and changing some of these variants at birth may not do anything at all." The article notes several startups are already providing predictions on intelligence. "In the United States, there are virtually no restrictions on the types of genetic predictions companies can offer, and no external vetting of their proprietary scoring methods."

Read more of this story at Slashdot.

"Eight healthy babies were born in Britain," reports Phys.org, "with the help of an experimental technique that uses DNA from three people to help mothers avoid passing devastating rare diseases to their children, researchers reported Wednesday." Mutations in mitochondrial DNA "can cause a range of diseases in children that can lead to muscle weakness, seizures, developmental delays, major organ failure and death," and in rare cases even pre-IVF testing can't clearly detect their presence. Researchers have been developing a technique that tries to avoid the problem by using the healthy mitochondria from a donor egg. They reported in 2023 that the first babies had been born using this method... Using this method means the embryo has DNA from three people — from the mother's egg, the father's sperm and the donor's mitochondria — and it required a 2016 U.K. law change to approve it. It is also allowed in Australia but not in many other countries, including the U.S. Experts at Britain's Newcastle University and Monash University in Australia reported in the New England Journal of Medicine Wednesday that they performed the new technique in fertilized embryos from 22 patients, which resulted in eight babies that appear to be free of mitochondrial diseases. One woman is still pregnant... Robin Lovell-Badge [a stem cell and developmental genetics scientist at the Francis Crick Institute who was not involved in the research] said the amount of DNA from the donor is insignificant, noting that any resulting child would have no traits from the woman who donated the healthy mitochondria... In the U.K., every couple seeking a baby born through donated mitochondria must be approved by the country's fertility regulator. As of this month, 35 patients have been authorized to undergo the technique. Critics have previously raised concerns, warning that it's impossible to know the impact these sorts of novel techniques might have on future generations... But in countries where the technique is allowed, advocates say it could provide a promising alternative for some families.

Read more of this story at Slashdot.

"Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March," writes a Washington Post technology columnist. "Now it's back with the same person in charge — and I still don't trust it." As of this week, genetic data from the more than 10 million remaining 23andMe customers has been formally sold to an organization called TTAM Research Institute for $305 million. That nonprofit is run by the person who co-founded and ran 23andMe, Anne Wojcicki. In a recent email to customers, the new 23andMe said it "will be operating with the same employees and privacy protocols that have protected your data." Never mind that Wojcicki and her privacy protocols are what put your DNA at risk in the first place... The company is legally obligated to maintain and honor 23andMe's existing privacy policies, user consents and data protection measures. And as part of a settlement with states, TTAM also agreed to provide annual privacy reports to state regulators and set up a privacy board. But it hasn't agreed to take the fundamental step of asking for permission to acquire existing customers' genetic information. And it's leaving the door open to selling people's genes to the highest bidder again in the future... Existing 23andMe customers have the right to delete their data or opt out of TTAM's research. But the new company is not asking for opt-in permission before it takes ownership of customers' DNA... Why does that matter? Because people who handed over the DNA 15 years ago, often to learn about their genetic ancestry, never imagined it might be used in this way now. Asking for new permission might significantly shrink the size (and value) of 23andMe's DNA database — but it would be the right thing to do given the rocky history. Neil M. Richards [the Washington University professor who served as privacy ombudsman for the bankruptcy court], pointed out that about a third of 23andMe customers haven't logged in for at least three years, so they may have no idea what is going on. Some 23andMe users never even clicked "agree" on a legal agreement that allowed their data to be sold like this; the word "bankruptcy" wasn't added to the company's privacy policy until 2022. And then there is an unknown number of deceased users who most certainly can't consent, but whose DNA still has an impact on their living genetic relatives... [S]everal states have argued that their existing genetic privacy laws don't allow 23andMe to receive the information without getting permission from every single person. Virginia has an ongoing lawsuit over the issue, and the California attorney general's office told me it "will continue to fight to protect and vindicate the rights" of consumers.... Two more points of concern: "There is nothing in 23andMe's bankruptcy agreement or privacy statement to prevent TTAM from selling or transferring DNA to some other organization in the future." The article also notes a 2023 data breach affecting 6.9 million users, arguing "They haven't shown they can keep your data safe... 23andMe's financial struggles could make it hard to run a robust cybersecurity program."

Read more of this story at Slashdot.

Researchers have created the world's first mRNA-based vaccine against a deadly, antibiotic-resistant bacterium — and they did it using the platform developed for COVID-19 vaccines. Medical Express publishes their announcement: The vaccine developed by the team from the Institute for Biological Research and Tel Aviv University is an mRNA-based vaccine delivered via lipid nanoparticles, similar to the COVID-19 vaccine. However, mRNA vaccines are typically effective against viruses like COVID-19 — not against bacteria like the plague... In 2023, the researchers developed a unique method for producing the bacterial protein within a human cell in a way that prompts the immune system to recognize it as a genuine bacterial protein and thus learn to defend against it. The researchers from Tel Aviv University and the Institute for Biological Research proved, for the first time, that it is possible to develop an effective mRNA vaccine against bacteria. They chose Yersinia pestis, the bacterium that causes bubonic plague — a disease responsible for deadly pandemics throughout human history. In animal models, the researchers demonstrated that it is possible to effectively vaccinate against the disease with a single dose. The team of researchers was led by Professor Dan Peer at Tel Aviv University, a global pioneer in mRNA drug development, who says the success of the current study now "paves the way for a whole world of mRNA-based vaccines against other deadly bacteria."

Read more of this story at Slashdot.

An anonymous reader quotes a report from the Associated Press: Filmmaker Peter Jackson owns one of the largest private collections of bones of an extinct New Zealand bird called the moa. His fascination with the flightless ostrich-like bird has led to an unusual partnership with a biotech company known for its grand and controversial plans to bring back lost species. On Tuesday, Colossal Biosciences announced an effort to genetically engineer living birds to resemble the extinct South Island giant moa -- which once stood 12 feet (3.6 meters) tall -- with $15 million in funding from Jackson and his partner Fran Walsh. The collaboration also includes the New Zealand-based Ngai Tahu Research Centre. "The movies are my day job, and the moa are my fun thing I do," said Jackson. "Every New Zealand schoolchild has a fascination with the moa." The moa had roamed New Zealand for 4,000 years until they became extinct around 600 years ago, mainly because of overhunting. A large skeleton brought to England in the 19th century, now on display at the Yorkshire Museum, prompted international interest in the long-necked bird. Unlike Colossal's work with dire wolves, the moa project is in very early stages. It started with a phone call about two years ago after Jackson heard about the company's efforts to "de-extinct" -- or create genetically similar animals to -- species like the woolly mammoth and the dire wolf. Then Jackson put Colossal in touch with experts he'd met through his own moa bone-collecting. At that point, he'd amassed between 300 and 400 bones, he said. In New Zealand, it's legal to buy and sell moa bones found on private lands, but not on public conservation areas -- nor to export them. The first stage of the moa project will be to identify well-preserved bones from which it may be possible to extract DNA, said Colossal's chief scientist Beth Shapiro. Those DNA sequences will be compared to genomes of living bird species, including the ground-dwelling tinamou and emu, "to figure out what it is that made the moa unique compared to other birds," she said. [...] The direction of the project will be shaped by Mori scholars at the University of Canterbury's Ngi Tahu Research Centre. Ngi Tahu archaeologist Kyle Davis, an expert in moa bones, said the work has "really reinvigorated the interest in examining our own traditions and mythology."

Read more of this story at Slashdot.

"Scientists have created the first lasers made entirely from edible materials," reports Science magazine "which could someday help monitor and track the properties of foods and medications with sensors that can be harmlessly swallowed." [The researchers' report] shows that tiny droplets of everyday cooking oils can act like echo chambers of light, otherwise known as lasers. By providing the right amount of energy to an atom, the atom's electrons will excite to a higher energy level and then relax, releasing a photon of light in the process. Trap a cloud of atoms in a house of mirrors and blast them with the right amount of energy, and the light emitted by one excited atom will stimulate one of its neighbors, amplifying the atoms' collective glow... [The researchers] shot purple light at droplets of olive oil, whose surfaces can keep photons of light bouncing around, trapping them in the process. This reflected light excited the electrons in the oil's chlorophyll molecules, causing them to emit photons that triggered the glow of other chlorophyll molecules — transforming the droplet into a laser. The energy of the chlorophyll's radiation depends on the oil droplets' size, density, and other properties. The study's authors suggest this sensitivity can be exploited to track different properties of food or pharmaceutical products. When researchers added oil droplets to foods and then measured changes in the laser light the droplets emitted, they could reliably infer the foods' sugar concentration, acidity, exposure to high temperatures, and growth of microorganisms. They also used the lasers to encode information, with droplets of different diameters functioning like the lines of a barcode. By mixing in sunflower oil droplets of seven specific sizes — all less than 100 microns wide — the researchers encoded a date directly into peach compote: 26 April, 2017, the first international Stop Food Waste Day. Thanks to long-time Slashdot reader sciencehabit for sharing the news.

Read more of this story at Slashdot.

alternative_right shares a report from ScienceAlert: The world's first commercial hybrid of silicon circuitry and human brain cells will soon be available for rent. Marketed for its vast potential in medical research, the biological machine, grown inside a British laboratory, builds on the Pong-playing prototype, DishBrain. Each CL1 computer is formed of 800,000 neurons grown across a silicon chip, and their life-support system. While it can't yet match the mind-blowing capabilities of today's most powerful computers, the system has one very significant advantage: it only consumes a fraction of the energy of comparable technologies. AI centers now consume countries' worth of energy, whereas a rack of CL1 machines only uses 1,000 watts and is naturally capable of adapting and learning in real time. [...] When neuroscientist Brett Kagan and colleagues pitted their creation against equivalent levels of machine learning algorithms, the cell culture systems outperformed them. Users can send code directly into the synthetically supported system of neurons, which is capable of responding to electrical signals almost instantly. These signals act as bits of information that can be read and acted on by the cells. But perhaps the greatest potential for this biological and synthetic hybrid is as an experimental tool for learning more about our own brains and their abilities, from neuroscience to creativity. The first CL1 units will reportedly ship soon for $35,000 each. Remote access can apparently be rented for $300 per week.

Read more of this story at Slashdot.

Beeftopia shares a report from CBS News: The U.S. government is preparing to breed billions of flies and dump them out of airplanes over Mexico and southern Texas to fight a flesh-eating maggot. That sounds like the plot of a horror movie, but it is part of the government's plans for protecting the U.S. from a bug that could devastate its beef industry, decimate wildlife and even kill household pets. This weird science has worked well before. The targeted pest is the flesh-eating larva of the New World Screwworm fly. The U.S. Department of Agriculture plans to ramp up the breeding and distribution of adult male flies -- sterilizing them with radiation before releasing them. They mate with females in the wild, and the eggs laid by the female aren't fertilized and don't hatch. There are fewer larvae, and over time, the fly population dies out. It is more effective and environmentally friendly than spraying the pest into oblivion, and it is how the U.S. and other nations north of Panama eradicated the same pest decades ago. Sterile flies from a factory in Panama kept the flies contained there for years, but the pest appeared in southern Mexico late last year. [...] The USDA expects a new screwworm fly factory to be up and running in southern Mexico by July 2026. It plans to open a fly distribution center in southern Texas by the end of the year so that it can import and distribute flies from Panama if necessary. The New World screwworm fly is a tropical species, unable to survive Midwestern or Great Plains winters, so it was a seasonal scourge. Still, the U.S. and Mexico bred and released more than 94 billion sterile flies from 1962 through 1975 to eradicate the pest, according to the USDA. The numbers need to be large enough that females in the wild can't help but hook up with sterile males for mating. One biological trait gives fly fighters a crucial wing up: Females mate only once in their weekslong adult lives. "A similar approach to certain species of mosquito is being debated," adds Beeftopia. "The impact on ecosystems is unclear."

Read more of this story at Slashdot.

"Researchers are embarking on an ambitious project to construct human genetic material from scratch," reports the Guardian, "to learn more about how DNA works and pave the way for the next generation of medical therapies." Scientists on the Synthetic Human Genome (SynHG) project will spend the next five years developing the tools and knowhow to build long sections of human genetic code in the lab. These will be inserted into living cells to understand how the code operates. Armed with the insights, scientists hope to devise radical new therapies for the treatment of diseases. Among the possibilities are living cells that are resistant to immune attack or particular viruses, which could be transplanted into patients with autoimmune diseases or with liver damage from chronic viral infections. "The information gained from synthesising human genomes may be directly useful in generating treatments for almost any disease," said Prof Jason Chin, who is leading the project at the MRC's Laboratory of Molecular Biology (LMB) in Cambridge... For the SynHG project, researchers will start by making sections of a human chromosome and testing them in human skin cells. The project involves teams from the universities of Cambridge, Kent, Manchester, Oxford and Imperial College London... Embedded in the project is a parallel research effort into the social and ethical issues that arise from making genomes in the laboratory, led by Prof Joy Zhang at the University of Kent. "We're a little way off having anything tangible that can be used as a therapy, but this is the time to start the discussion on what we want to see and what we don't want to see," said Dr Julian Sale, a group leader at the LMB.

Read more of this story at Slashdot.